Catalyst Capital Advisors’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.1K | Sell |
21
-19
| -48% | -$10.7K | ﹤0.01% | 366 |
|
|
2026
Q1 | $22.5K | Buy |
40
+10
| +33% | +$6.41K | ﹤0.01% | 335 |
|
|
2025
Q4 | $20.3K | Sell |
30
-10
| -25% | -$6.81K | ﹤0.01% | 347 |
|
|
2025
Q3 | $25.6K | Sell |
40
-10
| -20% | -$6.07K | ﹤0.01% | 413 |
|
|
2025
Q2 | $26.8K | Sell |
50
-14
| -22% | -$6.7K | ﹤0.01% | 425 |
|
|
2025
Q1 | $26.9K | Hold |
64
| – | – | ﹤0.01% | 403 |
|
|
2024
Q4 | $26.5K | Hold |
64
| – | – | ﹤0.01% | 418 |
|
|
2024
Q3 | $32.3K | Sell |
64
-16
| -20% | -$7.77K | ﹤0.01% | 383 |
|
|
2024
Q2 | $39K | Buy |
80
+1
| +1% | +$502 | ﹤0.01% | 268 |
|
|
2024
Q1 | $42.7K | Buy |
79
+1
| +1% | +$546 | ﹤0.01% | 256 |
|
|
2023
Q4 | $43.3K | Buy |
78
+17
| +28% | +$7.98K | ﹤0.01% | 231 |
|
|
2023
Q3 | $26.7K | Buy |
61
+15
| +33% | +$7.48K | ﹤0.01% | 296 |
|
|
2023
Q2 | $23.1K | Sell |
46
-4
| -8% | -$1.92K | ﹤0.01% | 305 |
|
|
2023
Q1 | $25K | Sell |
50
-15
| -23% | -$7.18K | ﹤0.01% | 285 |
|
|
2022
Q4 | $26.5K | Sell |
65
-1
| -2% | -$388 | ﹤0.01% | 288 |
|
|
2022
Q3 | $22K | Sell |
66
-1
| -1% | -$367 | ﹤0.01% | 310 |
|
|
2022
Q2 | $24K | Buy |
67
+9
| +16% | +$3.67K | ﹤0.01% | 314 |
|
|
2022
Q1 | $32K | Buy |
58
+11
| +23% | +$5.79K | ﹤0.01% | 348 |
|
|
2021
Q4 | $31K | Sell |
47
-4
| -8% | -$2.51K | ﹤0.01% | 326 |
|
|
2021
Q3 | $32K | Sell |
51
-1
| -2% | -$672 | ﹤0.01% | 319 |
|
|
2021
Q2 | $33K | Buy |
52
+1
| +2% | +$552 | ﹤0.01% | 333 |
|
|
2021
Q1 | $25K | Sell |
51
-9
| -15% | -$4.51K | ﹤0.01% | 313 |
|
|
2020
Q4 | $30K | Buy |
+60
| New | +$26.8K | ﹤0.01% | 290 |
|
|
2018
Q4 | – | Sell |
-11,350
| Closed | -$2.83M | – | 447 |
|
|
2018
Q3 | $2.83M | Sell |
11,350
-1,850
| -14% | -$449K | 0.09% | 108 |
|
|
2018
Q2 | $2.88M | Sell |
13,200
-1,200
| -8% | -$247K | 0.1% | 109 |
|
|
2018
Q1 | $2.76M | Sell |
14,400
-3,200
| -18% | -$591K | 0.1% | 109 |
|
|
2017
Q4 | $2.75M | Buy |
17,600
+400
| +2% | +$63K | 0.1% | 108 |
|
|
2017
Q3 | $2.67M | Buy |
17,200
+4,600
| +37% | +$727K | 0.12% | 116 |
|
|
2017
Q2 | $2.03M | Buy |
12,600
+12,210
| +3,131% | +$1.98M | 0.09% | 133 |
|
|
2017
Q1 | $60K | Sell |
390
-390
| -50% | -$53.8K | ﹤0.01% | 309 |
|
|
2016
Q4 | $92K | Sell |
780
-695
| -47% | -$79.3K | 0.01% | 280 |
|
|
2016
Q3 | $166K | Sell |
1,475
-1,325
| -47% | -$140K | 0.02% | 259 |
|
|
2016
Q2 | $260K | Buy |
+2,800
| New | +$240K | 0.05% | 244 |
|
|
2015
Q3 | – | Sell |
-7,100
| Closed | -$455K | – | 572 |
|
|
2015
Q2 | $455K | Buy |
+7,100
| New | +$492K | 0.05% | 245 |
|
Other funds holding IDXX
Catalyst Capital Advisors's IDXX Position: Q2 2026 in Review
Catalyst Capital Advisors reduced its Idexx Laboratories (IDXX) stake by 48% in Q2 2026, selling an estimated $10.7K and leaving 21 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #366.
Catalyst Capital Advisors first reported a position in IDXX in Q2 2015 and has held it in 34 quarters since. The position peaked at $2.88M in Q2 2018. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Catalyst Capital Advisors held 21 shares of Idexx Laboratories worth $11.1K as of Q2 2026.
- Catalyst Capital Advisors sold 19 Idexx Laboratories shares in Q2 2026, an estimated $10.7K.
- Idexx Laboratories made up ﹤0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #366 holding.
- Catalyst Capital Advisors first reported a position in Idexx Laboratories in Q2 2015 and has held it in 34 quarters since.
- Catalyst Capital Advisors's Idexx Laboratories position peaked at $2.88M in Q2 2018.
- 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.